| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 15,300 | 16,900 | 21.03. | |
| 16,300 | 17,100 | 20.03. |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.03. | Burning Rock Biotech GAAP EPS of -$0.02, revenue of $18.1M | 1 | Seeking Alpha | ||
| 12.03. | Burning Rock Biotech Limited: Burning Rock Reports Unaudited Fourth Quarter and Full Year 2025 Financial Results | 233 | GlobeNewswire (Europe) | GUANGZHOU, China, March 12, 2026 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the "Company" or "Burning Rock"), a company focused on the application of next-generation sequencing... ► Artikel lesen | |
| 05.01. | Burning Rock Biotech Limited: Burning Rock Announces Founder's Purchase of Its ADSs | 210 | GlobeNewswire (Europe) | GUANGZHOU, China, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the "Company" or "Burning Rock"), a company focusing on the application of next generation sequencing... ► Artikel lesen | |
| 23.12.25 | Burning Rock Biotech Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 23.12.25 | Burning Rock Biotech Limited: Burning Rock Announces Results of 2025 Annual General Meeting | 143 | GlobeNewswire (Europe) | GUANGZHOU, China, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the "Company" or "Burning Rock"), a company focusing on the application of next generation sequencing... ► Artikel lesen | |
| 01.12.25 | Burning Rock Biotech Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 01.12.25 | Burning Rock Biotech Limited: Burning Rock Announces 2025 Annual General Meeting to be Held on December 23, 2025 | 1 | GlobeNewswire (USA) | ||
| 28.11.25 | Burning Rock Stock Up 35%+ As Loss Narrows | 1 | Benzinga.com | ||
| BURNING ROCK BIOTECH Aktie jetzt für 0€ handeln | |||||
| 28.11.25 | Neglected Burning Rock charms investors with high margins, narrowing losses | 1 | Bamboo Works | ||
| 20.11.25 | Burning Rock Biotech GAAP EPS of -$0.02, revenue of $18.49M | 1 | Seeking Alpha | ||
| 20.11.25 | Burning Rock Biotech Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 20.11.25 | Burning Rock Biotech Limited: Burning Rock Reports Third Quarter 2025 Financial Results | 210 | GlobeNewswire (Europe) | GUANGZHOU, China, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the "Company" or "Burning Rock"), a company focused on the application of next generation sequencing... ► Artikel lesen | |
| 24.09.25 | Burning Rock Biotech Limited: Burning Rock's OncoGuide OncoScreen Plus CDx System Now Approved in Japan as a Companion Diagnostic for Capivasertib in Breast Cancer | 2 | GlobeNewswire (USA) | ||
| 08.09.25 | Burning Rock Biotech Limited: Burning Rock Reports Second Quarter 2025 Financial Results | 407 | GlobeNewswire (Europe) | GUANGZHOU, China, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the "Company" or "Burning Rock"), a company focused on the application of next generation sequencing... ► Artikel lesen | |
| 06.06.25 | Burning Rock Biotech Q1 Loss Narrows, Revenue Improves | 514 | AFX News | BEIJING (dpa-AFX) - Burning Rock Biotech Limited (BNR) Friday reported loss before tax of RMB 13.28 million for the first quarter, significantly lower than RMB 121.37 million loss in the same... ► Artikel lesen | |
| 06.06.25 | Burning Rock Biotech Limited: Burning Rock Reports First Quarter 2025 Financial Results | 1.248 | GlobeNewswire (Europe) | GUANGZHOU, China, June 06, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the "Company" or "Burning Rock"), a company focused on the application of next generation sequencing... ► Artikel lesen | |
| 25.03.25 | Burning Rock Biotech Limited Q4 Loss Drops | 511 | AFX News | BEIJING (dpa-AFX) - Burning Rock Biotech Limited (BNR) released Loss for fourth quarter of -RMB81.29 millionThe company's bottom line came in at -RMB81.29 million, or -RMB0.79 per share. This... ► Artikel lesen | |
| 25.03.25 | Burning Rock Biotech Limited: Burning Rock Reports Unaudited Fourth Quarter and Full Year 2024 Financial Results | 397 | GlobeNewswire (Europe) | GUANGZHOU, China, March 25, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the "Company" or "Burning Rock"), a company focused on the application of next generation sequencing... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 77,30 | +0,26 % | Bioxyne vs. BioNTech: Australisches MDMA-Biotech hebt Prognose nach starkem Halbjahr an | ||
| MEDIGENE | 0,030 | -15,73 % | Medigene: Zurückziehung - 18.11.2025 | ||
| QIAGEN | 34,805 | -1,28 % | Qiagen unter Druck, Zalando auf Erholungskurs: DAX-Ausblick | Der DAX befindet sich weiter auf Talfahrt. In der abgelaufenen Woche büßte das größte deutsche Börsenbarometer rund 144 Punkte ein und schloss -0,61% niedriger mit 23.447 Punkten. Die höchsten Verluste... ► Artikel lesen | |
| MODERNA | 44,100 | -0,54 % | Pfizer vs Moderna: Which Pharma Stock Has More Upside? | ||
| VALNEVA | 4,500 | -0,44 % | Valneva: Nettoverlust wegen Sondereffekt vervielfacht - Lyme-Daten entscheidend | Der Impfstoffhersteller Valneva hat im Geschäftsjahr 2025 einen Nettoverlust von 115,2 Millionen Euro ausgewiesen, nach einem Verlust von 12,2 Millionen Euro im Vorjahr. Der Vergleich ist jedoch durch... ► Artikel lesen | |
| NOVAVAX | 8,315 | -0,50 % | FOMO an der Wall Street: Novavax meldet überraschenden Gewinn - Aktie schießt zweistellig hoch | © Foto: picture alliance / Ulrich Baumgarten | Ulrich BaumgartenEin Ergebnis, das niemand erwartet hatte, gepaart mit neuen Big-Pharma-Deals: Novavax sorgt für FOMO an der Wall Street. Wie lange hält... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 40,600 | +1,50 % | Is CRISPR Therapeutics Stock a Buy Now? | ||
| REGENERON PHARMACEUTICALS | 632,00 | -0,32 % | EQS-News: Formycon AG: Formycon sichert Vermarktungsstart für Aflibercept-2mg-Biosimilar FYB203 in Europa und weiteren Territorien durch Settlement mit Regeneron und Bayer | EQS-News: Formycon AG
/ Schlagwort(e): Sonstiges
Formycon sichert Vermarktungsstart für Aflibercept-2mg-Biosimilar FYB203 in Europa und weiteren Territorien durch Settlement mit... ► Artikel lesen | |
| VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales | SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety... ► Artikel lesen | |
| OCUGEN | 1,759 | +1,24 % | Ocugen, Inc. - 8-K, Current Report | ||
| VIKING THERAPEUTICS | 27,835 | -0,50 % | Better Weight Loss Drug Stock Buy: Eli Lilly vs Viking Therapeutics | ||
| INTELLIA THERAPEUTICS | 11,120 | -0,54 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM | CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing... ► Artikel lesen | |
| SCORPIUS | 0,070 | 0,00 % | Scorpius Holdings, Inc. - 8-K, Current Report | ||
| EDITAS MEDICINE | 2,053 | +1,68 % | Is Editas Medicine Going to $0? | ||
| GENMAB | 219,40 | +1,11 % | Passing of Genmab A/S' Annual General Meeting | Company Announcement At Genmab A/S' Annual General Meeting held today March 19, 2026, the Annual Report for 2025 was approvedDischarge was given to the Board of Directors and the Executive Management... ► Artikel lesen |